EBV reactivation serological profile in primary Sjögren’s syndrome: an underlying trigger of active articular involvement?

Antibody to Epstein–Barr virus (EBV) early antigen diffuse (anti-EA-D) is associated with viral replication. However, their possible associations with clinical/therapeutic features in primary Sjögren’s syndrome (pSS) were not established. We evaluated 100 pSS patients (American–European Criteria) an...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology international 2013-05, Vol.33 (5), p.1149-1157
Main Authors: Pasoto, Sandra Gofinet, Natalino, Renato Romera, Chakkour, Henrique Pires, Viana, Vilma dos Santos Trindade, Bueno, Cleonice, Leon, Elaine Pires, Vendramini, Margarete Borges Gualhardo, Neto, Mauricio Levy, Bonfa, Eloisa
Format: Article
Language:English
Subjects:
Adult
Antibodies, Antinuclear - blood
Antibodies, Viral - blood
Antigens, Viral - immunology
Biomarkers - blood
Case-Control Studies
Chi-Square Distribution
Disease Progression
Enzyme-Linked Immunosorbent Assay
Female
Glucocorticoids - therapeutic use
Herpesvirus 4, Human - immunology
Humans
Immunoglobulin G - blood
Immunoglobulin M - blood
Immunosuppressive Agents - therapeutic use
Joints - drug effects
Joints - immunology
Joints - virology
Male
Medicine
Medicine & Public Health
Middle Aged
Original Article
Prednisone - therapeutic use
Rheumatology
Risk Factors
Severity of Illness Index
Sjogren's Syndrome - blood
Sjogren's Syndrome - diagnosis
Sjogren's Syndrome - drug therapy
Sjogren's Syndrome - immunology
Sjogren's Syndrome - virology
Virus Activation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antibody to Epstein–Barr virus (EBV) early antigen diffuse (anti-EA-D) is associated with viral replication. However, their possible associations with clinical/therapeutic features in primary Sjögren’s syndrome (pSS) were not established. We evaluated 100 pSS patients (American–European Criteria) and 89 age/gender/ethnicity-matched healthy controls. Disease activity was measured by EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI). Antibodies to EBV (anti-VCA IgG/IgM, anti-EBNA-1 IgG, anti-EA-D IgG) were determined by ELISA. Patients and controls had comparable frequencies and mean levels of anti-VCA IgG (90 vs. 86.5 %, p  = 0.501; 2.6 ± 1.1 vs. 2.5 ± 1.1 AU/mL, p  = 0.737) and anti-EBNA-1 IgG (92 vs. 94.4 %, p  = 0.576; 141.3 ± 69.8 vs. 135.6 ± 67.5 RU/mL, p  = 0.464). Anti-VCA IgM was negative in all cases. Noteworthy, higher frequency and increased mean levels of anti-EA-D were observed in patients than controls (36 vs. 4.5 %, p  
ISSN:0172-8172
1437-160X
DOI:10.1007/s00296-012-2504-3